ArticleFrontiers in neurology2025
Triglyceride-glucose index: a novel prognostic marker for sepsis-associated encephalopathy severity and outcomes.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of the atherogenic index of plasma and a novel triglyceride-glucose-body shape index with stroke: insights from NHANES and machine learning approaches.BMC cardiovascular disorders · 2026Article
- Prognostic Nutritional Index as a Novel Biomarker for Predicting Prognosis in Sepsis-Associated Encephalopathy: A Multicenter Retrospective Cohort Study.Emergency medicine international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated encephalopathy (SAE) is a complex condition with variable outcomes. This study investigates the potential of the Triglyceride-glucose (TyG) index as a marker for disease severity and prognosis in SAE patients. Methods: We conducted a retrospective cohort study using data from the Medical Information Mart for Intensive Care (MIMIC-IV) database. Patients with sepsis who were admitted to the intensive care unit (ICU) were categorized into two groups based on the occurrence of SAE. Key clinical outcomes were 90-day survival (primary outcome) and length of ICU and hospital stays, as well as the use of vasoactive medications (secondary outcomes). The TyG index was calculated, and its association with disease severity scores and patient outcomes was analyzed using statistical methods, including survival analysis, Cox regression, and correlation analyses. Results: The study population's median age was 65.96 years, predominantly male (60.1%). Higher TyG index scores correlated with elevated clinical severity scores (APSIII, LODS, OASIS, SAPSII, and CCI) and increased ICU and hospital stay durations. TyG index categorization revealed significant differences in 90-day survival probabilities, with "high TyG" associated with a 25% increased mortality risk compared to "low TyG." Furthermore, TyG index showed a moderate positive correlation with ICU stay duration and use of norepinephrine and vasopressin, but not with dopamine and epinephrine use. Conclusion: The TyG index is a significant independent predictor of disease severity and prognosis in SAE patients. High TyG levels correlate with worse clinical outcomes and increased mortality risk, suggesting its potential as a valuable tool in managing SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.